T cell activation by recombinant FcεRI γ-chain immune receptors:: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition

被引:44
作者
Hombach, A
Heuser, C
Gerken, M
Fischer, B
Lewalter, K
Diehl, V
Pohl, C
Abken, H
机构
[1] Univ Cologne, Innere Med Klin 1, Lab Tumorgenet, D-50924 Cologne, Germany
[2] Evangel Krankenhaus Koln Kalk, Cologne, Germany
关键词
recombinant immune receptor; Fc epsilon RI gamma-chain; scFv; Hodgkin's disease; CD30;
D O I
10.1038/sj.gt.3301195
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
T cells can be endowed with antigen specificity by grafting with a chimeric receptor consisting of an extracellular antigen binding moiety (scFv) derived from an antibody and an intracellular signaling domain. Conflicting data exist on the impact of an extracellular spacer domain between the antigen binding and the signaling domain with respect to cellular activation. Here, we recorded conjugate formation and antigen-driven cellular activation of T cells grafted with receptor molecules that contain the same antigen binding site (anti-CD30 HRS3-scFv) and signaling domain (Fc epsilon Rl gamma-chain), however, with and without an IgG1 CH2CH3 (Fc) spacer domain between the scFv and transmembrane moiety. Receptors of both configurations mediate equally efficient conjugate formation between receptor grafted T cells and antigen-positive target cells. Specific signaling by the spacer containing receptor, however, is blocked by five- to 10-fold lower concentrations of soluble antigen than by the spacerless receptor indicating a higher avidity of the spacer containing receptor to soluble antigen. In contrast, cellular activation upon binding to antigen-positive cells is mediated more efficiently by the spacer-less receptor. This demonstrates that the extracellular spacer domain impairs antigen-dependent cellular activation by the chimeric immune receptor, but not intercellular conjugate formation.
引用
收藏
页码:1067 / 1075
页数:9
相关论文
共 19 条
[1]   Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? [J].
Abken, H ;
Hombach, A ;
Reinhold, U ;
Ferrone, S .
IMMUNOLOGY TODAY, 1998, 19 (01) :2-5
[2]  
Altenschmidt U, 1997, J IMMUNOL, V159, P5509
[3]   CHARACTERIZATION OF A HUMANIZED BISPECIFIC MONOCLONAL-ANTIBODY FOR CANCER-THERAPY [J].
BRUYNCK, A ;
SEEMANN, G ;
BOSSLET, K .
BRITISH JOURNAL OF CANCER, 1993, 67 (03) :436-440
[4]  
DIEHL V, 1984, J CANCER RES CLIN, V101, P411
[5]  
ENGERT A, 1990, CANCER RES, V50, P2929
[6]   SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA-SUBUNIT OR ZETA-SUBUNIT OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS [J].
ESHHAR, Z ;
WAKS, T ;
GROSS, G ;
SCHINDLER, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :720-724
[7]   ENDOWING T-CELLS WITH ANTIBODY SPECIFICITY USING CHIMERIC T-CELL RECEPTORS [J].
GROSS, G ;
ESHHAR, Z .
FASEB JOURNAL, 1992, 6 (15) :3370-3378
[8]  
Hombach A, 1998, CANCER RES, V58, P1116
[9]  
Hombach A, 1998, SCAND J IMMUNOL, V48, P497
[10]   Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies [J].
Hombach, A ;
Pohl, C ;
Heuser, C ;
Sircar, R ;
Diehl, V ;
Abken, H .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 218 (1-2) :53-61